Summary:
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of the Study Drug in Adult Subjects with Moderate-to-Severe Atopic Dermatitis Inadequately Controlled by Topical Treatments
Criteria:- Male or female aged ≥18 and ≤80 years of age.
- Chronic AD that has been present for at least 3 years.
- Documented recent history of inadequate response to treatment with topical medications such as topical corticosteroids, calcineurin inhibitors, or crisaborole for at least 4 weeks in the 6 months, or subjects for whom these topical treatments are otherwise medically inadvisable.
- Involvement of at least 10% or more of BSA (body surface area).
Qualified Participants May Receive:
$200-$400 per in person visit. Total $4,000+.